All In Biotech

Drug Trial Radar · NCT01263015

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Last checked: Nov 20, 2026Latest source record: Apr 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 844 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

844

Actual

Start

Feb 1, 2011

Primary completion

May 14, 2012

Study completion Dec 3, 2015

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Shionogi; GlaxoSmithKline
First posted
Dec 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.

Conditions

  • Infection, Human Immunodeficiency Virus I

Interventions

  • DolutegravirDrug

    Dolutegravir (also known as GSK1349572) 50 mg taken once daily

  • AtriplaDrug

    Atripla once daily on an empty stomach

  • Abacavir/LamivudineDrug

    taken once daily; also known as EPZICOM

  • Abacavir/Lamivudine PlaceboDrug

    matching placebo taken once daily

  • Dolutegravir placeboDrug

    matching placebo taken once daily

  • Atripla placeboDrug

    matching placebo taken once daily on an empty stomach

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48Time frame: Week 48

Locations

145 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Hobson City, Alabama

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Beach, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Maywood, Illinois

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Valhalla, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.